tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Nephritis, Hereditary D009394 1 associated lipids
Skin Diseases, Papulosquamous D017444 2 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Collagen Diseases D003095 2 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Anemia, Refractory D000753 3 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Tongue Diseases D014060 2 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Discitis D015299 2 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Pityriasis Lichenoides D017514 2 associated lipids
Histiocytosis D015614 2 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Rupture D012421 2 associated lipids
Lichen Nitidus D017513 1 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Porokeratosis D017499 1 associated lipids
Dermatitis, Perioral D019557 4 associated lipids
Scleritis D015423 3 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Intertrigo D007402 1 associated lipids
Impetigo D007169 3 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Pterygium D011625 3 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Mucinoses D017520 2 associated lipids
Carcinoma, Merkel Cell D015266 2 associated lipids
Nocturia D053158 1 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Malacoplakia D008287 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Platz KP et al. Causes of death following liver transplantation in FK 506- and cyclosporine-treated patients. 1994 Transplant. Proc. pmid:7527952
Christe W Neurological disorders in liver and kidney transplant recipients. 1994 Transplant. Proc. pmid:7527953
Felldin M et al. Rescue therapy with Tacrolimus (FK506) in renal transplant recipients--a multicenter analysis. 1995 Transplant. Proc. pmid:8540032
Bersztel A et al. Deoxyspergualin is synergistic with cyclosporin A, but not with FK506 in a rat heart allograft transplantation model. 1995 Transplant. Proc. pmid:8540095
Tze WJ et al. Prolongation of pig islet xenograft survival in rats by local immunosuppression with FK 506. 1994 Transplant. Proc. pmid:7513471
Starzl TE FK 506 versus cyclosporine. 1993 Transplant. Proc. pmid:7679820
Fukuzaki T et al. Nonvascularized islet xenograft rejection in a mouse-to-rat combination where the vascularized heart is rapidly rejected. 1994 Transplant. Proc. pmid:7513472
Garcia CD et al. Renal transplantation in children less than six years old. 2001 Nov-Dec Transplant. Proc. pmid:11750527
First International Congress on FK 506. August 21-24, 1991, Pittsburgh, PA. 1991 Transplant. Proc. pmid:1721253
Smoter P et al. Risk factors of acute renal failure after orthotopic liver transplantation: single-center experience. 2014 Transplant. Proc. pmid:25380918
Mendez R FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group. 1998 Transplant. Proc. pmid:9636522
Yuan QS et al. Rescue therapy with tacrolimus in renal graft patients with cyclosporine A-induced hepatotoxicity: a preliminary study. 2000 Transplant. Proc. pmid:11119896
Kahl A et al. First results with a quadruple therapy regimen including tacrolimus and mycophenolate mofetil in patients after combined pancreas and kidney transplantation. 1998 Transplant. Proc. pmid:9532149
Sánchez-Fructuoso AI et al. The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. 2009 Jul-Aug Transplant. Proc. pmid:19715905
Asensio M et al. Experience with tacrolimus as primary immunosuppressor in pediatric liver transplant. 2002 Transplant. Proc. pmid:11959208
Brook NR et al. Prograf produces a molecular environment favoring antifibrosis, an effect reversed by the addition of rapamune. 2005 Jan-Feb Transplant. Proc. pmid:15808577
Bond MMK et al. Cyclosporine Versus Tacrolimus: Which Calcineurin Inhibitor Has Influence on Cytomegalovirus Infection in Cardiac Transplantation? 2018 Transplant. Proc. pmid:29661443
Nalesnik MA et al. The effect of FK 506 and CyA on the Lewis rat renal ischemia model. 1990 Transplant. Proc. pmid:1689911
McCauley J et al. FK 506 in the management of nephrotic syndrome after renal transplantation. 1993 Transplant. Proc. pmid:7680154
Farghali H et al. FK 506 modulates D-galactosamine-induced hepatitis in rats. 1991 Transplant. Proc. pmid:1721285
Andrews WS et al. Comparison of cyclosporine- vs tacrolimus-based immunosuppression in pediatric liver transplantation. 1996 Transplant. Proc. pmid:8623452
Cantarovich M et al. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. 1998 Transplant. Proc. pmid:9636592
Hachida M et al. Combined use of deoxyspergualin and FK 506 for temporary circulatory assist. 1999 Transplant. Proc. pmid:10455968
Harihara Y et al. Correlation between graft size and necessary tacrolimus dose after living-related liver transplantation. 2000 Transplant. Proc. pmid:11120116
van Hooff JP et al. Tacrolimus and glucose metabolism. 1999 Transplant. Proc. pmid:10576044
Soriano S et al. Single-center experience with initial intravenous dosing of tacrolimus after kidney transplantation. 1999 Transplant. Proc. pmid:10576045
Torio A et al. Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients. 2012 Transplant. Proc. pmid:23146466
Yoshimura N et al. Combination therapy of tacrolimus (FK506) with azathioprine and steroids in renal transplant recipients. 1998 Transplant. Proc. pmid:9474949
Asano T et al. Increased tacrolimus trough levels in association with severe diarrhea, a case report. 2004 Transplant. Proc. pmid:15518758
Kim SJ et al. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients. 2004 Transplant. Proc. pmid:15518759
Boran M et al. Determining renal resistive and pulsatility indexes long-term after kidney transplantation in kidney transplant recipients on cyclosporine a-, tacrolimus-, or sirolimus-based regimens. 2014 Transplant. Proc. pmid:24935296
Woo J et al. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. 1990 Transplant. Proc. pmid:1697112
Woo J et al. Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis. 1990 Transplant. Proc. pmid:1697113
Valdivia LA et al. Complement and target cells belong to the same species after liver xenografting: protection from hyperacute rejection. 1994 Transplant. Proc. pmid:7518123
Laftavi MR et al. African American renal transplant recipients (RTR) require higher tacrolimus doses to achieve target levels compared to white RTR: does clotrimazole help? 2013 Transplant. Proc. pmid:24314941
Klintmalm GB et al. Rejection: FK 506 for rescue or maintenance. 1993 Transplant. Proc. pmid:7682356
Mor E et al. Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study. 1995 Transplant. Proc. pmid:7533363
Jiang H et al. Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. 1991 Transplant. Proc. pmid:1721317
Falkiewicz K et al. Tacrolimus decreases tubular phosphate wasting in renal allograft recipients. 2003 Transplant. Proc. pmid:14529892
Reggiani P et al. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation. 2005 Transplant. Proc. pmid:15919435
Ge J et al. Impact of FOXP3 Polymorphisms on the Blood Level of Tacrolimus in Renal Transplant Recipients. Transplant. Proc. pmid:27569929
Kapturczak MH et al. Pharmacology of calcineurin antagonists. 2004 Transplant. Proc. pmid:15041303
Yang SS et al. A single center, open-label, randomized pilot study to evaluate the safety and efficacy of tacrolimus modified release, Advagraf, versus tacrolimus twice daily, Prograf, in stable renal recipients (single). 2015 Transplant. Proc. pmid:25891697
Jin KB et al. Effects of tacrolimus on antioxidant status and oxidative stress in glioma cells. 2008 Transplant. Proc. pmid:18929850
Hranjec T et al. Benign transient hyperphosphatasemia associated with Epstein-Barr virus enteritis in a pediatric liver transplant patient: a case report. 2008 Transplant. Proc. pmid:18589195
Troisi R et al. Are reduced tacrolimus dosages needed in the early postoperative period following living donor liver transplantation in adults? 2002 Transplant. Proc. pmid:12176470
Varo E et al. Alternative immunosuppression for acute renal failure in liver transplantation: role of ultra-low dose tacrolimus and basiliximab. 2002 Transplant. Proc. pmid:12176471
Ochiai T et al. Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group. 1995 Transplant. Proc. pmid:7533419
Saito S et al. The pattern of rejection and susceptibility to different kinds of immunosuppression after combined liver, duodenum, and pancreas transplantation in swine--immunosuppressive drugs versus ex vivo immunomodulation of the allograft. 1995 Transplant. Proc. pmid:7533420
Daoud AJ et al. A comparison of the safety and efficacy of mycophenolate mofetil, prednisone and cyclosporine and mycophenolate mofetil, and prednisone and tacrolimus. 1998 Transplant. Proc. pmid:9865303
Takaya S et al. Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. 1991 Transplant. Proc. pmid:1721348
Tashiro H et al. Monitoring for engraftment of rat orthotopic liver transplantation by semiquantitative PCR. 1995 Transplant. Proc. pmid:7533421
Braun F et al. How to handle mycophenolate mofetil in combination with tacrolimus? 1998 Transplant. Proc. pmid:9865309
Morel P et al. Liver retransplantation in adults: overall results and determinant factors affecting the outcome. 1991 Transplant. Proc. pmid:1721349
Zegarska J et al. Tacrolimus Metabolite M-III May Have Nephrotoxic and Myelotoxic Effects and Increase the Incidence of Infections in Kidney Transplant Recipients. 2016 Transplant. Proc. pmid:27496443
Yuan-Xin L et al. Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China. 2010 Jan-Feb Transplant. Proc. pmid:20172275
Colak T et al. Effect of conversion from cyclosporine to tacrolimus on lipid profiles in renal transplant recipients. 2002 Transplant. Proc. pmid:12270321
Woodside KJ et al. Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile. 2005 Transplant. Proc. pmid:15919491
Sánchez-Pérez B et al. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients. 2008 Transplant. Proc. pmid:19010171
Ye Q et al. Persistence of donor cells and incidence of graft-versus-host disease after simultaneous small bowel and bone marrow transplantation. 1996 Transplant. Proc. pmid:8907895
Waller JR et al. Primary immunosuppression with tacrolimus is associated with a reduction in renal allograft fibrosis compared with neoral therapy. 2002 Transplant. Proc. pmid:12176496
Ribes D et al. Combined use of tacrolimus and sirolimus in de novo renal transplant patients: current data. 2005 Jul-Aug Transplant. Proc. pmid:16182816
Sato K et al. Effectiveness of triple regimen immunosuppression in canine pancreatic allotransplantation. 1994 Transplant. Proc. pmid:7520628
Yamada K et al. Short-term FK 506-induced morphological changes in rat kidneys. 1991 Transplant. Proc. pmid:1721381
Hattori R et al. FK 506 in cadaveric kidney transplantation from non-heart-beating donors. 1998 Transplant. Proc. pmid:9838666
Fischer L et al. Hepatitis G virus infection in liver transplant recipients. 1999 Feb-Mar Transplant. Proc. pmid:10083208
Goller AL et al. Loss of serum bicarbonate after discordant liver xenotransplantation. 2000 Transplant. Proc. pmid:10936383
Scott-Douglas N et al. Treatment of acute renal transplant rejection with FK 506 in patients on cyclosporine after failure of standard antirejection therapy. 1996 Transplant. Proc. pmid:8962226
Boots JM et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. 2002 Transplant. Proc. pmid:12176542
Cho JH et al. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. 2012 Transplant. Proc. pmid:22310591
Ji SM et al. Conversion from cyclosporine to tacrolimus for chronic allograft nephropathy. 2007 Transplant. Proc. pmid:17580148
Opelz G New immunosuppressants and HLA matching. 2001 Feb-Mar Transplant. Proc. pmid:11266911
Wang X et al. Intraportal FK 506 improves intrahepatic islet allograft survival. 1991 Transplant. Proc. pmid:1721412
Nishimura Y et al. Whole organ vascularized thymus allografting effectively modulates cardiac rejection. 1996 Transplant. Proc. pmid:8658660
Fu F et al. Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. 1999 Feb-Mar Transplant. Proc. pmid:10083555
Tatekawa Y et al. Intragraft expression of p38 in rat small bowel transplantation. 2000 Transplant. Proc. pmid:10995948
Karamperis N et al. Comparison of the pharmacokinetics of tacrolimus and cyclosporine at equivalent molecular doses. 2003 Transplant. Proc. pmid:12826146
Budde K et al. Long-term outcome of tacrolimus rescue therapy in late rejection after renal transplantation. 1998 Transplant. Proc. pmid:9723280
Dopazo C et al. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. 2009 Transplant. Proc. pmid:19376416
Baran DA et al. Can initial tacrolimus trough levels be predicted from clinical variables? 2004 Transplant. Proc. pmid:15621157
Land W et al. Tacrolimus versus cyclosporine in primary simultaneous pancreas-kidney transplantation: preliminary results at 1 year of a large multicenter trial. 2002 Transplant. Proc. pmid:12176625
El-Safa EA et al. Paradoxical response to tacrolimus assessed by interleukin-2 gene expression. 2006 Transplant. Proc. pmid:17175263
Moura Neto A et al. Frequency of Thyroid Dysfunction in Patients With Diabetes Mellitus Before and After Liver Transplantation. 2018 Transplant. Proc. pmid:29661439
Sperschneider H A large, multicentre trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267291
Wada H et al. Dose response to FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721444
Shapiro R Tacrolimus in solid organ transplantation: an update. 1999 Transplant. Proc. pmid:10500545
Duzova A et al. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. 2003 Transplant. Proc. pmid:14697926
McMaster P and Buist L FK 506 in transplantation. 1993 Transplant. Proc. pmid:7689275
Morales E et al. Conversion from cyclosporine to FK 506 as rescue therapy in renal transplantation with poorly steroid-responsive acute rejection. 1999 Transplant. Proc. pmid:10500562
Martins L et al. Conversion to tacrolimus in case-problem kidney transplant recipients under cyclosporine-based immunosuppression. 2000 Transplant. Proc. pmid:11134735
Nardo B et al. Evidence of microchimerism after pretransplant blood transfusion and FK 506 in liver xenograft. 2000 Transplant. Proc. pmid:11134771
Fritsche L et al. Late conversion to mycophenolate mofetil for chronic deterioration of renal allograft function. 1998 Transplant. Proc. pmid:9723451
Fornairon S et al. Can we improve the results of simultaneous pancreas-kidney transplantation? 1998 Transplant. Proc. pmid:9745580
Hanack U et al. Is there a different impact of cyclosporine versus tacrolimus on delayed graft function after kidney transplantation? 1998 Transplant. Proc. pmid:9723477
Miyata Y et al. Development of xenogeneic microchimerism correlated with graft outcome in hamster-to-rat heart xenotransplantation. 1998 Transplant. Proc. pmid:9723548
Mohsin N et al. Low tacrolimus dose requirements in renal transplant recipients in the omani population: implications for pharmacogenetics? 2005 Transplant. Proc. pmid:16213259
Lee CM et al. Monotherapy with tacrolimus for heart and liver transplant: a case report. 2014 Transplant. Proc. pmid:24767396
Lo A et al. Ganciclovir prophylaxis for cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone. 2001 Feb-Mar Transplant. Proc. pmid:11267516
Malinowski K et al. Effect of different anti-rejection regimens on the expression of differentiation and activation markers on the surface of host lymphocytes. 2000 Transplant. Proc. pmid:10856579
Matsumoto S et al. ET-Kyoto ductal injection and density-adjusted purification combined with potent anti-inflammatory strategy facilitated single-donor islet transplantation: case reports. 2010 Jul-Aug Transplant. Proc. pmid:20692433